{
  "docId": "019de072-ef20-75e9-922b-a59946a49f08",
  "docSlug": "b6265fe9aad535c251b3bd786fc797fa",
  "documentTitle": "BioAtla | Investor Conference Presentation Deck | 15 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 15,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "The slide uses a series of overlapping circles to connect key company attributes to strategic goals.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de072-ef20-75e9-922b-a59946a49f08/14",
  "deckHref": "/decks/019de072-ef20-75e9-922b-a59946a49f08",
  "deckJsonHref": "/decks/019de072-ef20-75e9-922b-a59946a49f08.json",
  "deckAnchorHref": "/decks/019de072-ef20-75e9-922b-a59946a49f08#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.9,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "Overlapping circles representing company pillars",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ed529b04-cee6-41f4-ab94-1a7fe0492b06",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.07,
        "y": 0.35
      },
      "kind": "list",
      "text": "Proprietary technology; Broad applicability; Spans multiple tumors",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3e00037b-2e1d-4d8d-8160-8cde19445d45",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.2,
        "x": 0.3,
        "y": 0.3
      },
      "kind": "list",
      "text": "Two lead CAB-ADC assets in Phase 2; Interim Phase 2 data w/ 3011 supports advancing in multiple sarcoma indications; Near-term catalysts",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c4f2412f-c7ac-4ff1-b28a-46d467e1b759",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.2,
        "x": 0.75,
        "y": 0.3
      },
      "kind": "list",
      "text": "Strong cash position $219.4MM (at end 1Q22) with runway into 2H24; Sufficient through key clinical milestones",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c6dfb291-0f84-4e2a-ab69-9a6ef1b59240",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.15,
        "x": 0.53,
        "y": 0.35
      },
      "kind": "list",
      "text": "Diversified and robust pipeline; Strategic optionality",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cd432f7d-b9e1-4372-a617-3daad708512c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.7
      },
      "kind": "paragraph",
      "text": "Execute on clinical programs; Create long-term sustainable value; Build core commercial capabilities",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "46b5f067-1695-4e39-bdac-df0101e17bf9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "BioAtla is a clinical stage company focused on transforming cancer therapy with Conditionally Active Biologics (CABs)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5b2f80e0-10d4-493e-a6d6-c40abcd50b42",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "654204f1-786d-4e89-9a02-c2761db0557d",
      "evidence": "BioAtla is a clinical stage company focused on transforming cancer therapy with Conditionally Active Biologics (CABs)",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}